GSK3-α/β Inhibition Attenuates Progression of CKD in Lepr-/- Mice with Type 2 Diabetes (T2D) Beyond Standard-of-Care Therapy (SOC) with Metformin/Ramipril/Empagliflozin

Motrapu Manga, Lidia Anguiano-Gomez, Maria Lucia Angelotti, Paola Romagnani, Hans J. Anders, “SK3-α/β Inhibition Attenuates Progression of CKD in Lepr-/- Mice with Type 2 Diabetes (T2D) Beyond Standard-of-Care Therapy (SOC) with Metformin/Ramipril/Empagliflozin,” Am. Soc. Nephrol. Kidney Week Abstract Supplement: FR-PO191 2019.